Clinical trial
Topotecan and Paclitaxel in Treating Patients With Recurrent or Metastatic…
NCT00003065 · Herbert Irving Comprehensive Cancer Center, Other · Completed
Key facts
| NCT number | NCT00003065 |
|---|---|
| Title | Topotecan and Paclitaxel in Treating Patients With Recurrent or Metastatic Cancer of the Cervix |
| Official title | Phase II Investigation of Topotecan and Taxol in Patients With Recurrent/Metastatic Cancer of the Cervix |
| Lead sponsor | Herbert Irving Comprehensive Cancer Center, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cervical Cancer |
| Intervention type | Biological, Drug |
| Interventions | filgrastim, paclitaxel, topotecan hydrochloride |
| Enrollment | 25 |
| Start date | Jan 1, 1997 |
| Completion | Feb 1, 2004 |
| First posted | Jan 27, 2003 |
| Last update posted | Jan 6, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: